• Futura Medical assessing commercialisation options for CBD100

    Futura Medical assessing commercialisation options for CBD100

    James Barder interview with Proactive Investor

  • Futura Medical's Ken James updates on EU and US regulatory progress for MED3000

    Futura Medical's Ken James updates on EU and US regulatory progress for MED3000

    Ken James interview with Proactive Investor

  • Regulatory submissions for MED3000 remain on track

    Regulatory submissions for MED3000 remain on track

    James Barder, Chief Executive interview with Proactive Investor’s Andrew Scott

  • Full Year Results for the year ended 31 December 2019

    Full Year Results for the year ended 31 December 2019

    April 2020

    James Barder, Chief Executive interview with Proactive Investor’s Andrew Scott

  • Interview with Executive Director and Head of R&D - EU regulatory update and analysis of FM57

    Interview with Executive Director and Head of R&D - EU regulatory update and analysis of FM57

    January 2020

    Ken James speaks to Proactive Investor’s Andrew Scott following positive initial discussions with EU regulators after an extensive internal evaluation of the clinical data from the Phase 3 study (“FM57”).

  • Interview with Executive Director and Head of R&D - Phase III Results

    Interview with Executive Director and Head of R&D - Phase III Results

    December 2019

    Ken James speaks to Proactive London's Andrew Scott following the read-out from the phase III clinical trial of its erectile dysfunction gel.

  • Fireside chat - Ken James & Dr Wayne Hellstrom

    Fireside chat - Ken James & Dr Wayne Hellstrom

    November 2019

    Fireside chat with Ken James & Dr Wayne Hellstrom

  • Interview of CEO – Interims

    Interview of CEO – Interims

    September 2019

    James Barder caught up with Proactive London's Andrew Scott to talk through the company's interim results.

  • Introduction to Futura

    Introduction to Futura

    James Barder introduces Futura and its lead product MED2005

  • Fireside Chat

    Fireside Chat

    February 2019

    Fireside chat with Professor David Ralph and Ken James

  • Research & Development seminar

    February 2019

    Research & Development seminar on MED2005

    Watch video
  • Milestone for Futura Medical

    Milestone for Futura Medical

    Interview of Ken James, Head of R&D, by Proactive Investors in which he discusses milestone for Futura Medical

  • On track with Phase 3 trial

    On track with Phase 3 trial

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses their Phase 3 trial

  • New safety data on lead treatment

    New safety data on lead treatment

    Interview of Ken James, Head of R&D, by Proactive Investors in which he discusses new safety data on lead treatment

  • Futura Medical doses first patient in Phase 3 study

    Futura Medical doses first patient in Phase 3 study

    Interview of Angela Hildreth, FD and COO, by Proactive Investors in which she discusses the first patient in its Phase 3 clinical study of MED2005

  • MED2005 treatment clinical trial set to begin

    MED2005 treatment clinical trial set to begin

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses MED2005

  • Phase 3 study kick off

    Phase 3 study kick off

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the lead asset MED2005

  • MED2005 Clinical Programme Update

    MED2005 Clinical Programme Update

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the first Phase 3 efficacy trial for MED2005

  • Preliminary results for the year ended 31 December 2017

    Preliminary results for the year ended 31 December 2017

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the progress across Futura's portfolio of products.

  • MED2005 interview

    MED2005 interview

    Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the recent article published by the Journal of Sexual Medicine.

  • MED2005 update

    MED2005 update

    Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the start of the PK study and provides a regulatory, clinical and commercial update.

  • Positive market research data on MED2005

    Positive market research data on MED2005

    Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the positive market research data on MED2005 announced on 16 October 2017.

  • Interim results

    Interim results

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the Interim results for the period ending 30 June 2017 including the Phase 3 programme for MED2005 and the strategy for CSD500.

  • Church and Dwight license termination

    Church and Dwight license termination

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the change of priorities which sees Futura Medical distributor terminate licensing agreement.

  • Critical step in the development of MED2005

    Critical step in the development of MED2005

    Video Interview of James Barder discussing a 'critical step' in the development of MED2005

  • Preliminary results

    Preliminary results

    Video Interview of James Barder discussing the Preliminary results for the year ended 31 December 2016

  • Significant interest for MED2005

    Significant interest for MED2005

    Video Interview of James Barder discussing the significant interest for MED2005, Futura’s erectile dysfunction gel based on Ipsos research

  • UK licensing agreement

    UK licensing agreement

    Video Interview of James Barder discussing the UK licensing agreement for its pain relief gel TPR100 and the launch of CSD500 in Saudi Arabia